Mannitol In Baddi

MOQ100 Case/Cases

Drug TypeInjection

IngredientsMannitol& Glycerine

Physical FormLiquid

FunctionOther

Recommended ForIt is a diuretic used to increase urine production and to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g. cerebral edema glaucoma kidney failure).

Quantity1000 Pieces

Molecular FormulaC6H14O6

Molar Mass182.17 g/mol

Purity99%

AppearanceWhite crystalline powder

SolubilityWater soluble

Melting Point166-168 °C

Packaging Size100 ml

CompositionMannitol Glycerin

FormInjection

BrandMytobest-G

ManufacturerBiochemix Healthcare

MaterialPlastic

Concentration20% w/v

Volume100ml

PackagingGlass bottle

StorageRoom temperature

Mannitol TypePharmaceutical grade

FeaturesIV Infusion Sterile Safe Effective Reliable

MOQ5 Piece/Pieces

Shelf Life3 years

SizeAvailable in 100g 500g 2.5kg 5kg packs

Storage InstructionsStore at 10-30AdegC in a tightly sealed container keep away from moisture and direct sunlight

UsageFor laboratory use only not for drug household or other uses

Physical StatePowder

Ph Level7.4 A+- 0.2 at 25AdegC

MOQ100 Piece/Pieces

Drug TypeInjection

Physical FormLiquid

Recommended ForHuman Being

DosageAs per suggestion

Storage InstructionsDry Place

Base materialAgar

PH7.4

Plate diameter150mm

PackagingSterile plates

Storage2-8°C

Shelf life2 years

Dosage FormPowder

Product TypeCulture media

PackagingBottle

Weight500g

Dimensions15x10cm

MaterialPlastic bottle

StorageRoom temperature

Chemical FormulaC6H8(OH)6

AppearanceWhite Crystalline

SolubilityWater-soluble

Purity99% min

Packaging25kg Bags

UsageFood additive pharmaceutical excipient and renal function testing.

MOQ10000 Bottle/Bottles

Origin of MedicineIndia

Dosage FormLiquid

Pacakaging (Quantity Per Box)100ml per bottle

IndicationDescription : Mannitol I.V. injection is indicated for the following purposes in adults and pediatric patients. Therapeutic Use Promotion of diuresis in the prevention or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. Reduction of intracranial pressure and brain mass. Reduction of high intraocular pressure when the pressure cannot be lowered by other means. Promotion of urinary excretion of toxic materials.

Salt CompositionDescription : Mannitol I.V. injection is indicated for the following purposes in adults and pediatric patients. Therapeutic Use Promotion of diuresis in the prevention or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. Reduction of intracranial pressure and brain mass. Reduction of high intraocular pressure when the pressure cannot be lowered by other means. Promotion of urinary excretion of toxic materials.

Drug TypeSpecific Drug

Product TypeMedical solution

Volume350 ml

MaterialGlass bottle

PurityUSP grade

Concentration20%

SterilitySterile

MOQ25 Kilograms/Kilograms

Pacakaging (Quantity Per Box)10 Bottles

Salt CompositionMannitol USP

Packaging TypePlastic Bottle

Origin of MedicineIndian

Dosage FormGranules

IndicationUsed in oliguric phase of acute renal failure to promote diuresis

MOQ100 Bag/Bags

Vapor Density1.6AA+-0.1 g/cm3

AssayAssay kit provides a simple and direct procedure for measuring D -mannitol in a variety of samples including fruit and juices

Melting Point167-170AAoC

Water SolubilitySoluble in water very slightly soluble in ethanol

Physical FormPowder

Boiling point494.9AA+-0.0 AAdegC at 760 mmHg

Product NameMannitol Powder IP

Product TypePowder

Primary ColorBrown

Packaging25kg Bag

Purity99%

Mesh Size100-200